37 results about "Chondroitin sulphate" patented technology

Improved treatments of joint diseases, such as, e.g. osteoarthritis and rheumatoid arthritis, and pain, wherein a strontium-containing compound is administered alone or in combination with one or more second therapeutically and / or prophylactically active substances, selected from the group consisting of bisphosphonates, glucosamine, pallitative agents, analgesic agents, disease modifying anti-rheumatic compounds (DMARDs), selective estrogen receptor modulators (SERMs), aromatase inhibitors, non-steroidal anti-inflammatory agents (NSAIDs), COX-2 inhibitors, COX-3 inhibitors, opioids, inhibitors / antagonists of IL-1, inhibitors / antagonists of TNF-alpha, inhibitors of matrix metallo-proteinases (MMPs), cathepsin K inhibitors, inhibitors / antagonists of RANK-ligand, statins, glucocorticoids, chondroitin sulphate, NMDA receptor antagonists, inhibitors of interleukin-I converting enzyme, Calcitonin gene related peptide antagonists, glycine antagonists, vanilloid receptor antagonists, inhibitors of inducible nitric oxide synthetase (iNOS), N-acetylcholine receptor agonists, neurokinin antagonists, neuroleptic agents, PAR2 receptor antagonists and anabolic growth factors acting on joint tissue components. Pharmaceutical compositions comprising a strontium-containing compound and a second therapeutically and / or prophylactically active substance as defined above.

Methods for reducing chronic pain caused by a disrupted spinal disc are described. In one method, a physiologically acceptable amount of an injectable is injected into the disc. The injectable is obtained from a stock solution comprising chondroitin sulphate, glucosamine HCl, aqueous solution of dextrose; sodium carboxymethylcellulose, and a buffer substance in quantity to bring the pH of the stock solution to a value above about 6.0. Water is also added to dilute the stock solution. The stock solution may further comprise an anesthetic such as bupivicaine.

The invention relates to composition comprising a dextran-tyramine conjugate and a conjugate selected from the group consisting of chondroitin sulphate-tyramine, collagen-tyramine, chitosan-tyramine, chitosan-phloretic acid, gelatine-tyramine, heparan sulphate-tyramine, keratin sulphate-tyramine, hyaluronic acid-tyramine and heparin-tyramine.

The present invention relates to an injectable bone regeneration material containing a bone formation enhancing peptide, and more particularly, to an injectable bone regeneration material, in which a bone formation enhancing peptide essentially containing one and more amino acid sequences among SEQ ID NO: 1 to SEQ ID NO: 28 is bonded or mixed to a gel-forming base material selected from the group consisting of chitosan, alginic acid, silk fibroin, propylene glycol, propylene glycol alginic acid, poloxamer, chondroitin sulphate, and the combination thereof. The injectable bone regeneration material according to the present invention can increase differentiation of bone marrow stromal cells and osteoblasts into bone tissue, thus maximizing tissue regeneration by a peptide capable of promoting differentiation of bone tissue and periodontal tissue regeneration. The injectable bone regeneration material is in the form of a gel, and thus can be applied to a surface of various medical devices such as implant etc., and can be mixed with bone graft particles to apply, so that it can increase a treatment effect of existing medical devices to maximize a tissue regeneration effect.

The present invention relates to nucleic acid molecules related to the var2csa gene family as well as amino acid sequences encoded by such nucleic acid molecules with respect to their role in mediating adhesion of infected red blood cells to chondroitin sulphate A (CSA) in the placenta which is characteristic for the pathogenesis of pregnancy associated malaria (PAM). Accordingly, The invention provides the use compounds that are related to VAR2CSA polypeptides var2csa nucleic acid molecules as medicaments, as well as it provides pharmaceutical compositions, in particular immunological compositions and vaccines, hereunder nucleotide-based vaccines comprising these compounds. In addition, the invention provides the use of the compounds mentioned for the manufacture of compositions, such as immunogenic compositions. Other aspects of the invention relates to methods of treatment and prevention of pregnancy associated malaria wherein these methods are based on the nucleic acid molecules and polypeptides the invention. As these compounds can also be used as biotechnological tools the invention provides in vitro diagnostic methods and kits comprising reagents and IgGs / antibodies designated to the use in such methods. The invention also relates to methods of identifying agents capable of modulating the VAR2CSA dependent adhesion to CSA and agent capable of interacting with VAR2CSA. Finally, a method for identifying polypeptides, which will induce a specific IgG / antibody response upon administration to a subject is provided by the invention.

Compositions and methods are provided for promoting elastin fiber formation (elastogenesis) in a cell, including methods that comprise contacting a cell that is capable of elastogenesis with (i) a mutated biglycan polypeptide that lacks chondroitin sulphate proteoglycan chains, (ii) a versican V3 isoform polypeptide that lacks most or all of the polypeptide regions encoded by one or more of exons 4, 5 or 6 or by exons 9-10 or 11-13, and / or with (iii) metastatin.

The invention relates to an implant or gel including at least one compound having magnetic functionality, which in turn includes a substrate of at least one enzyme involved in regenerating the extracellular matrix and a plurality of magnetic particles. The invention also relates to a compound having magnetic functionality which includes a substrate of at least one enzyme involved in regenerating the extracellular matrix and a plurality of magnetic particles, preferably with no coating or surface modification, or functionalised with carboxyl groups, for the production of an implant or gel for monitoring an enzymatic activity involved in regenerating the extracellular matrix. The substrate is preferably selected from the group that comprises collagen, chondroitin sulphate and hyaluronic acid, and the magnetic particles are superparamagnetic particles.

The invention discloses a method for extracting bioactive substances from an eggshell membrane. The method for extracting the bioactive substances from the eggshell membrane comprises the following steps: separating an eggshell membrane, smashing, carrying out enzymolysis, and extracting the bioactive substances, wherein eggshell membrane powder is treated by adopting ionic liquid before enzymolysis is carried out, and the ionic liquid is 1-hydroxyethyl-3-methylimidazole tetrafluoroborate. The method for extracting the bioactive substances from the eggshell membrane has the advantages that enzymolysis efficiency is improved, combined separation and extraction of keratin, hyaluronic acid and chondroitin sulphate is realized, and bioactive substance extraction also can be simplified, and environmental requirement is met.

The present invention provides a chondroitinase AC mutant, the amino acid sequence of which is shown in SEQ ID NO:2. The present invention also provides a method for preparing the AC mutant of chondroitinase sulfate. The present invention constructs the chondroitinase AC mutant by mutating the 170th position in the wild-type chondroitinase AC amino acid sequence SEQ ID NO:1 to glycine, thus reducing the chondroitinase AC mutant and polysaccharide The steric hindrance of substrate binding expands its binding pocket with polysaccharides, making it easier to bind polysaccharide substrates, thereby increasing the activity of chondroitinase AC.

The present invention relates to treatment of neuronal injury. The present invention discloses a novel use of an agent and a novel method for promoting neurite out growth and / or neural regeneration in CNS injuries. A novel mechanism of promoting neurite outgrowth by increasing the interaction of chondroitin sulphate proteoglycan (CSPG) to receptor protein tyrosine phosphatase sigma (RPTPσ) is disclosed.